Cargando…
Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease
Alpha-synuclein is considered the major pathological protein associated with Parkinson’s disease, but there is still no effective immunotherapy which targets alpha-synuclein. In order to create a safer and more effective therapy against PD, we are targeting an epitope of alpha-synuclein rather than...
Autores principales: | Shen, Ning, Song, Ge, Yang, Haiqiang, Lin, Xiaoyang, Brown, Breanna, Hong, Yuzhu, Cai, Jianfeng, Cao, Chuanhai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539124/ https://www.ncbi.nlm.nih.gov/pubmed/31083520 http://dx.doi.org/10.3390/ijms20092338 |
Ejemplares similares
-
Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer’s Disease
por: Fihurka, Oksana, et al.
Publicado: (2023) -
Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease
por: Fitzgerald, Emily, et al.
Publicado: (2019) -
Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease
por: Cersosimo, Maria Graciela
Publicado: (2015) -
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011) -
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)